<DOC>
	<DOCNO>NCT01332292</DOCNO>
	<brief_summary>This study investigate effect dose flutucasone furoate asthmatic subject age 5-11 year age . A randomized , two-way crossover , placebo control , 14 day treatment period , investigate safety , tolerability , pharmacokinetics serum cortisol level .</brief_summary>
	<brief_title>Pharmacokinetics PharmacoDynamics GW685698 Paedeatric Asthmatic Patients</brief_title>
	<detailed_description>This study investigate effect dose fluticasone furoate 100 μg ( microgram ) asthmatic subject age 5-11 year age . Fluticasone furoate currently development inhale corticosteroid component combination product contain inhaled corticosteroid long-acting beta-agonist . The study randomize two-way crossover , placebo control . During treatment period subject receive daily dose via novel dry powder inhaler 14 day . Approximately 26 subject recruit study , aim 20 complete study . Safety , tolerability , pharmacokinetics serum cortisol level investigate .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male premenarchial female subject age 511 year last planned treatment day eligible study . Premenarchial female define female yet begin menses consider Tanner Stage 2 less . Diagnosis asthma least 6 month prior screen . Patients must control exist asthma treatment screen define Childhood Asthma Control Test score &gt; 19 PEF ( Peak Expiratory Flow ) ≥80 % predict . Apart asthma , eczema rhinitis , subject healthy suffer significant medical condition . Subjects must take stable regimen short act betaagonist inhaler asneed basis least 4 week prior screen . Subjects must weigh least 15 kg ( kilogram ) . Subjects must demonstrate ability accept effectively use fluticasone furoate device use demonstration kit provide site . Subjects parents/guardians must able understand comply protocol requirement , instruction protocolstated restriction . Parents/guardians must ability read , write record diary information collect throughout study . They must also ability manage study drug administration PEF assessment . A signed date write informed consent least one parent/guardian , accompany inform assent subject prior admission study . Subjects change asthma medication within 4 week screen subject currently treat inhaled corticosteroid receive treatment within 4 week screen . In addition , subject currently receive ( receive within 4 week screen ) follow asthma therapy : theophylline , longacting inhaled betaagonists oral betaagonists . Any medical condition circumstance make volunteer unsuitable participation study ( e.g . history lifethreatening asthma ) . Any clinically relevant abnormality identify screen medical assessment , include asthma exacerbation require systemic corticosteroid ( oral , intramuscular , intravenous ) emergency room attendance within 3 month asthma exacerbation require hospitalization within 6 month prior screen . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week screen lead change asthma management , opinion Investigator , expect affect subject 's asthma status subject 's ability participate study . Clinical visual evidence oral candidiasis screening . Parent/guardian history psychiatric disease , intellectual deficiency , substance abuse , condition ( e.g. , inability read , comprehend write ) limit validity consent participate study . Any adverse reaction include immediate delay hypersensitivity beta2agonist , sympathomimetic drug , intranasal , inhaled systemic corticosteroid therapy . Known suspected sensitivity constituent novel dry powder inhaler ( i.e. , lactose magnesium stearate ) , example , history severe milk protein allergy . A subject eligible study he/she immediate family member participate Investigator , subInvestigator , study coordinator , employee participate Investigator . Children ward state government . Evidence clinically significant abnormality 12lead ECG ( electrocardiogram ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>inhalation profile</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharyngometry</keyword>
	<keyword>asthma</keyword>
	<keyword>pediatric subject</keyword>
	<keyword>GW685698</keyword>
	<keyword>Fluticasone furoate</keyword>
	<keyword>safety</keyword>
</DOC>